Pages that link to "Q41637922"
Jump to navigation
Jump to search
The following pages link to Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer (Q41637922):
Displaying 33 items.
- Cloning and sequencing of human βIII-tubulin cDNA: induction of βIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents (Q28262585) (← links)
- Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer (Q28290608) (← links)
- Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study (Q28379036) (← links)
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group (Q33566395) (← links)
- Oral chemotherapy in the treatment of hormone-refractory prostate cancer (Q33860003) (← links)
- Chemotherapy for androgen- independent prostate cancer: myth or reality (Q34108009) (← links)
- Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment (Q34138145) (← links)
- Treatment options in hormone-refractory prostate cancer: current and future approaches (Q34481266) (← links)
- Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice (Q34595748) (← links)
- Prostate Cancer and Bone Metastases: Medical Treatment (Q35576800) (← links)
- Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action (Q36588623) (← links)
- Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (Q36673680) (← links)
- End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice (Q37921009) (← links)
- Second‐line therapy for castrate‐resistant prostate cancer: A literature review (Q37925129) (← links)
- Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. (Q38745926) (← links)
- Systemic therapy of prostate cancer. new concepts from prostate cancer tumor biology (Q40488406) (← links)
- Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study (Q40559728) (← links)
- Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate (Q40682505) (← links)
- Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? (Q41251318) (← links)
- Therapy for hormone-resistant prostate cancer: no longer a myth (Q41547284) (← links)
- Surrogate endpoints (Q42390152) (← links)
- Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer (Q42548235) (← links)
- PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex (Q44962364) (← links)
- A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer (Q46495105) (← links)
- Treatment options for hormone-refractory prostate cancer (Q46764368) (← links)
- Therapy of hormone-refractory prostate cancer (Q46823511) (← links)
- Estramustine Phosphate Sodium (Q56519091) (← links)
- Oral estramustine and oral etoposide for hormone-refractory prostate cancer (Q57905130) (← links)
- Chemotherapy for endocrine-therapy-refractory prostate cancer (Q71662330) (← links)
- Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer (Q72069880) (← links)
- Anti-Angiogenic Treatment with Linomide as Adjuvant to Surgical Castration in Experimental Prostate Cancer (Q73589315) (← links)
- High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy (Q73944620) (← links)
- Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression (Q88313848) (← links)